A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Conditions: Ductal Breast Carcinoma In Situ; HER2/Neu Positive Interventions: Biological: Granulocyte-Macrophage Colony-Stimulating Factor; Biological: Multi-epitope HER2 Peptide Vaccine H2NVAC; Procedure: Therapeutic Conventional Surgery Sponsors: Mayo Clinic; National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | HER2 | Research | Vaccines